LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab.

    Manalac, Justin / Yee, Jennifer / Calayag, Kyle / Nguyen, Linda / Patel, Payal M / Zhou, Daniel / Shi, Run-Zhang

    Clinica chimica acta; international journal of clinical chemistry

    2020  Volume 510, Page(s) 687–690

    Abstract: Background: We report our findings of test performance especially specificity of a fully automated Abbott Architect anti-SARS-CoV-2 CMIA IgG and Euroimmun anti-SARS-CoV-2 ELISA IgA/IgG in human plasma.: Methods: We used positive cohort of 97 samples ... ...

    Abstract Background: We report our findings of test performance especially specificity of a fully automated Abbott Architect anti-SARS-CoV-2 CMIA IgG and Euroimmun anti-SARS-CoV-2 ELISA IgA/IgG in human plasma.
    Methods: We used positive cohort of 97 samples from Covid-19 patients or healthcare workers, collected at late time points from symptom onsets. We also included another cohort of 215 samples as negative controls, 78 of which had positive serology test results of other infectious diseases or autoimmunity. Assay specificity was assessed by using a total of 847 anonymized samples which were collected before the Covid-19 pandemic from local patient populations seeking clinical care for rheumatoid diseases, thyroid cancer, and therapeutic drug monitoring.
    Results: Abbott IgG, Euroimmun IgG/IgA had high precision, demonstrated by both intra- and inter-day CVs of <2%. There was no Abbott or Euroimmun IgG assay cross reactivity in the 78 samples with positive serology of non-SARS-CoV-2 infectious diseases and positive autoimmune antibodies. The Abbott IgG has specificity of 99.6%, while Euroimmun IgG and IgA were as high as 91.5% and 71.5%, respectively.
    Conclusions: Our evaluation confirmed high specificity of the Abbott IgG assay, while it was lower for Euroimmun IgG. Euroimmun IgA has suboptimal specificity which may limit its clinical use. Assay sensitivity was high for both Abbott and Euroimmun IgG assays.
    MeSH term(s) Betacoronavirus/immunology ; Enzyme-Linked Immunosorbent Assay/methods ; Humans ; Immunoglobulin A/blood ; Immunoglobulin A/immunology ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Limit of Detection ; Luminescent Measurements ; SARS-CoV-2
    Chemical Substances Immunoglobulin A ; Immunoglobulin G
    Keywords covid19
    Language English
    Publishing date 2020-09-08
    Publishing country Netherlands
    Document type Evaluation Study ; Journal Article
    ZDB-ID 80228-1
    ISSN 1873-3492 ; 0009-8981
    ISSN (online) 1873-3492
    ISSN 0009-8981
    DOI 10.1016/j.cca.2020.09.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results.

    Wang, Hannah / Wiredja, Danica / Yang, Lu / Bulterys, Philip L / Costales, Cristina / Röltgen, Katharina / Manalac, Justin / Yee, Jennifer / Zehnder, James / Shi, Run Zhang / Boyd, Scott D / Pinsky, Benjamin A

    Clinical chemistry

    2021  Volume 67, Issue 7, Page(s) 977–986

    Abstract: Background: Laboratory-based methods for SARS-CoV-2 antibody detection vary widely in performance. However, there are limited prospectively-collected data on assay performance, and minimal clinical information to guide interpretation of discrepant ... ...

    Abstract Background: Laboratory-based methods for SARS-CoV-2 antibody detection vary widely in performance. However, there are limited prospectively-collected data on assay performance, and minimal clinical information to guide interpretation of discrepant results.
    Methods: Over a 2-week period, 1080 consecutive plasma samples submitted for clinical SARS-CoV-2 IgG testing were tested in parallel for anti-nucleocapsid IgG (anti-N, Abbott) and anti-spike IgG (anti-S1, EUROIMMUN). Chart review was conducted for samples testing positive or borderline on either assay, and for an age/sex-matched cohort of samples negative by both assays. CDC surveillance case definitions were used to determine clinical sensitivity/specificity and conduct receiver operating characteristics curve analysis.
    Results: There were 52 samples positive by both methods, 2 positive for anti-N only, 34 positive for anti-S1 only, and 27 borderline for anti-S1. Of the 34 individuals positive for anti-S1 alone, 8 (24%) had confirmed COVID-19. No anti-S1 borderline cases were positive for anti-N or had confirmed/probable COVID-19. The anti-N assay was less sensitive (84.2% [95% CI 72.1-92.5%] vs 94.7% [95% CI 85.4-98.9%]) but more specific (99.2% [95% CI 95.5-100%] vs 86.9% [95% CI 79.6-92.3%]) than anti-S1. Abbott anti-N sensitivity could be improved to 96.5% with minimal effect on specificity if the index threshold was lowered from 1.4 to 0.6.
    Conclusion: Real-world concordance between different serologic assays may be lower than previously described in retrospective studies. These findings have implications for the interpretation of SARS-CoV-2 IgG results, especially with the advent of spike antigen-targeted vaccination, as a subset of patients with true infection are anti-N negative and anti-S1 positive.
    MeSH term(s) Adult ; Antibodies, Viral/blood ; Area Under Curve ; COVID-19/diagnosis ; COVID-19/virology ; Case-Control Studies ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Immunoglobulin G/blood ; Male ; Middle Aged ; Nucleocapsid/immunology ; ROC Curve ; Reagent Kits, Diagnostic ; Retrospective Studies ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/metabolism ; Spike Glycoprotein, Coronavirus/immunology
    Chemical Substances Antibodies, Viral ; Immunoglobulin G ; Reagent Kits, Diagnostic ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
    Language English
    Publishing date 2021-03-31
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    DOI 10.1093/clinchem/hvab045
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab

    Manalac, Justin / Yee, Jennifer / Calayag, Kyle / Nguyen, Linda / Patel, Payal M. / Zhou, Daniel / Shi, Run-Zhang

    Clinica Chimica Acta

    2020  Volume 510, Page(s) 687–690

    Keywords Clinical Biochemistry ; Biochemistry ; Biochemistry, medical ; General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 80228-1
    ISSN 1873-3492 ; 0009-8981
    ISSN (online) 1873-3492
    ISSN 0009-8981
    DOI 10.1016/j.cca.2020.09.002
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article: Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab

    Manalac, Justin / Yee, Jennifer / Calayag, Kyle / Nguyen, Linda / Patel, Payal M / Zhou, Daniel / Shi, Run-Zhang

    Clin Chim Acta

    Abstract: BACKGROUND: We report our findings of test performance especially specificity of a fully automated Abbott Architect anti-SARS-CoV-2 CMIA IgG and Euroimmun anti-SARS-CoV-2 ELISA IgA/IgG in human plasma. METHODS: We used positive cohort of 97 samples from ... ...

    Abstract BACKGROUND: We report our findings of test performance especially specificity of a fully automated Abbott Architect anti-SARS-CoV-2 CMIA IgG and Euroimmun anti-SARS-CoV-2 ELISA IgA/IgG in human plasma. METHODS: We used positive cohort of 97 samples from Covid-19 patients or healthcare workers, collected at late time points from symptom onsets. We also included another cohort of 215 samples as negative controls, 78 of which had positive serology test results of other infectious diseases or autoimmunity. Assay specificity was assessed by using a total of 847 anonymized samples which were collected before the Covid-19 pandemic from local patient populations seeking clinical care for rheumatoid diseases, thyroid cancer, and therapeutic drug monitoring. RESULTS: Abbott IgG, Euroimmun IgG/IgA had high precision, demonstrated by both intra- and inter-day CVs of <2%. There was no Abbott or Euroimmun IgG assay cross reactivity in the 78 samples with positive serology of non-SARS-CoV-2 infectious diseases and positive autoimmune antibodies. The Abbott IgG has specificity of 99.6%, while Euroimmun IgG and IgA were as high as 91.5% and 71.5%, respectively. CONCLUSIONS: Our evaluation confirmed high specificity of the Abbott IgG assay, while it was lower for Euroimmun IgG. Euroimmun IgA has suboptimal specificity which may limit its clinical use. Assay sensitivity was high for both Abbott and Euroimmun IgG assays.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #747275
    Database COVID19

    Kategorien

  5. Article: SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness.

    Röltgen, Katharina / Wirz, Oliver F / Stevens, Bryan A / Powell, Abigail E / Hogan, Catherine A / Najeeb, Javaria / Hunter, Molly / Sahoo, Malaya K / Huang, ChunHong / Yamamoto, Fumiko / Manalac, Justin / Otrelo-Cardoso, Ana R / Pham, Tho D / Rustagi, Arjun / Rogers, Angela J / Shah, Nigam H / Blish, Catherine A / Cochran, Jennifer R / Nadeau, Kari C /
    Jardetzky, Theodore S / Zehnder, James L / Wang, Taia T / Kim, Peter S / Gombar, Saurabh / Tibshirani, Robert / Pinsky, Benjamin A / Boyd, Scott D

    medRxiv : the preprint server for health sciences

    2020  

    Abstract: SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, could offer protective immunity, and may affect clinical outcomes of COVID-19 ... ...

    Abstract SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, could offer protective immunity, and may affect clinical outcomes of COVID-19 patients. We analyzed 625 serial plasma samples from 40 hospitalized COVID-19 patients and 170 SARS-CoV-2-infected outpatients and asymptomatic individuals. Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals. The development of plasma antibodies was correlated with decreases in viral RNAemia, consistent with potential humoral immune clearance of virus. Using a novel competition ELISA, we detected antibodies blocking RBD-ACE2 interactions in 68% of inpatients and 40% of outpatients tested. Cross-reactive antibodies recognizing SARS-CoV RBD were found almost exclusively in hospitalized patients. Outpatient and asymptomatic individuals' serological responses to SARS-CoV-2 decreased within 2 months, suggesting that humoral protection may be short-lived.
    Keywords covid19
    Language English
    Publishing date 2020-08-17
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2020.08.15.20175794
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.

    Röltgen, Katharina / Powell, Abigail E / Wirz, Oliver F / Stevens, Bryan A / Hogan, Catherine A / Najeeb, Javaria / Hunter, Molly / Wang, Hannah / Sahoo, Malaya K / Huang, ChunHong / Yamamoto, Fumiko / Manohar, Monali / Manalac, Justin / Otrelo-Cardoso, Ana R / Pham, Tho D / Rustagi, Arjun / Rogers, Angela J / Shah, Nigam H / Blish, Catherine A /
    Cochran, Jennifer R / Jardetzky, Theodore S / Zehnder, James L / Wang, Taia T / Narasimhan, Balasubramanian / Gombar, Saurabh / Tibshirani, Robert / Nadeau, Kari C / Kim, Peter S / Pinsky, Benjamin A / Boyd, Scott D

    Science immunology

    2020  Volume 5, Issue 54

    Abstract: SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, can neutralize the virus. It is, however, unknown which features of the ... ...

    Abstract SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, can neutralize the virus. It is, however, unknown which features of the serological response may affect clinical outcomes of COVID-19 patients. We analyzed 983 longitudinal plasma samples from 79 hospitalized COVID-19 patients and 175 SARS-CoV-2-infected outpatients and asymptomatic individuals. Within this cohort, 25 patients died of their illness. Higher ratios of IgG antibodies targeting S1 or RBD domains of spike compared to nucleocapsid antigen were seen in outpatients who had mild illness versus severely ill patients. Plasma antibody increases correlated with decreases in viral RNAemia, but antibody responses in acute illness were insufficient to predict inpatient outcomes. Pseudovirus neutralization assays and a scalable ELISA measuring antibodies blocking RBD-ACE2 interaction were well correlated with patient IgG titers to RBD. Outpatient and asymptomatic individuals' SARS-CoV-2 antibodies, including IgG, progressively decreased during observation up to five months post-infection.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Angiotensin-Converting Enzyme 2/blood ; Angiotensin-Converting Enzyme 2/genetics ; Angiotensin-Converting Enzyme 2/immunology ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; COVID-19/blood ; COVID-19/genetics ; COVID-19/immunology ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Male ; Middle Aged ; Real-Time Polymerase Chain Reaction ; SARS-CoV-2/genetics ; SARS-CoV-2/immunology ; Severity of Illness Index ; Spike Glycoprotein, Coronavirus/blood ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus ; spike glycoprotein, SARS-CoV ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Language English
    Publishing date 2020-12-08
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2470-9468
    ISSN (online) 2470-9468
    DOI 10.1126/sciimmunol.abe0240
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness

    Röltgen, Katharina / Wirz, Oliver F / Stevens, Bryan A / Powell, Abigail E / Hogan, Catherine A / Najeeb, Javaria / Hunter, Molly / Sahoo, Malaya K / Huang, ChunHong / Yamamoto, Fumiko / Manalac, Justin / Otrelo-Cardoso, Ana R / Pham, Tho D / Rustagi, Arjun / Rogers, Angela J / Shah, Nigam H / Blish, Catherine A / Cochran, Jennifer R / Nadeau, Kari C /
    Jardetzky, Theodore S / Zehnder, James L / Wang, Taia T / Kim, Peter S / Gombar, Saurabh / Tibshirani, Robert / Pinsky, Benjamin A / Boyd, Scott D

    medRxiv

    Abstract: SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, could offer protective immunity, and may affect clinical outcomes of COVID-19 ... ...

    Abstract SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, could offer protective immunity, and may affect clinical outcomes of COVID-19 patients. We analyzed 625 serial plasma samples from 40 hospitalized COVID-19 patients and 170 SARS-CoV-2-infected outpatients and asymptomatic individuals. Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals. The development of plasma antibodies was correlated with decreases in viral RNAemia, consistent with potential humoral immune clearance of virus. Using a novel competition ELISA, we detected antibodies blocking RBD-ACE2 interactions in 68% of inpatients and 40% of outpatients tested. Cross-reactive antibodies recognizing SARS-CoV RBD were found almost exclusively in hospitalized patients. Outpatient and asymptomatic individuals9 serological responses to SARS-CoV-2 decreased within 2 months, suggesting that humoral protection may be short-lived.
    Keywords covid19
    Language English
    Publishing date 2020-08-17
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2020.08.15.20175794
    Database COVID19

    Kategorien

To top